恩替卡韦联合茵芪肝复颗粒对慢性乙型肝炎肝硬化患者临床效果观察

目的 探讨分析恩替卡韦联合茵芪肝复颗粒对慢性乙型肝炎肝硬化患者的临床效果。方法 选取2016年1月至2018年9月收治的130例慢性乙型肝炎肝硬化患者随机分为观察组和对照组,观察组给予恩替卡韦联合茵芪肝复颗粒治疗,对照组给予恩替卡韦治疗,比较两组临床疗效,治疗前后肝功能指标、肝纤维化指标、LSM(肝硬度)。结果 观察组临床疗效总有效率为93.85%,较对照组显著提高(P＜0.05),治疗前两组肝功能指标、肝纤维化指标、LSM无统计学差异(P＞0.05),治疗后两组ALT、AST、TBIL、HA、LN、PC-Ⅲ、IV-C水平、LSM均显著下降,且治疗后观察组ALT、AST、TBIL、HA、LN、PC-Ⅲ、IV-C水平、LSM较对照组下降更显著(P＜0.05)。结论 恩替卡韦联合茵芪肝复颗粒治疗慢性乙型肝炎肝硬化可显著提高临床疗效,改善患者肝功能,控制肝脏纤维化,降低肝脏硬度,建议在临床上推广。

Clinical observation of entecavir combined with Yinzhiganfu granulein patients with chronic hepatitis B cirrhosis

Objective To investigate the clinical effect of entecavir combined with Yinzhiganfu Granule on patients with chronic hepatitis B cirrhosis.Methods To select 130 patients with chronic hepatitis B cirrhosis admitted from January 2016 to September 2018 and divide them into observation group and control group randomly.The observation group was given entecavir plus Yinzhiganfu granules,and the control group was given entecavir.To compare the clinical efficacy of the two groups,liver function indicators before and after treatment,liver fibrosis index,LSM (liver hardness).Results The total effective rate of clinical observation was 93.85%,which was significantly higher than that of the control group (P＜0.05).There was no significant difference in liver function index,liver fibrosis index and LSM between the two groups before treatment (P＞0.05).The levels of ALT,AST,TBIL,HA,LN,PC-III,IV-C and LSM were significantly decreased in the two groups,and the levels of ALT,AST,TBIL,HA,LN,PC-III and IV-C were observed in the observation group.LSM decreased more significantly than the control group (P＜0.05).Conclusion Entecavir combined with Yinzhiganfu Granule can significantly improve the clinical efficacy,improve liver function,control liver fibrosis and reduce liver stiffness.Promoted clinically.